Back to top

cell-therapy: Archive

Zacks Equity Research

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

RHHBYPositive Net Change CORTNegative Net Change LCTXNegative Net Change BTTXNo Net Change

Shaun Pruitt

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

AZNNegative Net Change PFENegative Net Change MRNANegative Net Change

Zacks Equity Research

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

DVAXPositive Net Change MRKNegative Net Change SGENPositive Net Change CORTNegative Net Change

Zacks Equity Research

Agilent (A) Boosts Genomic Profiling With New Collaboration

Agilent (A) collaborates with the National Cancer Centre Singapore to accelerate Asian-prevalent cancer research over the next two years.

ANegative Net Change AMATNegative Net Change ASURNegative Net Change ANETNegative Net Change

Zacks Equity Research

Iovance (IOVA) Up Despite FDA's Delayed Decision on Melanoma Drug

Iovance (IOVA) rises despite the FDA's postponement of the decision date regarding the regulatory filing for its lead candidate, lifileucel, to treat advanced melanoma due to resource constraints.

DVAXPositive Net Change MRKNegative Net Change CORTNegative Net Change IOVANegative Net Change